Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R55" target="_blank" >RIV/61988987:17110/17:A1801R55 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/17:10362456 RIV/00843989:_____/17:E0106326 RIV/00064165:_____/17:10362456
Výsledek na webu
<a href="http://dx.doi.org/10.1111/bjh.14549" target="_blank" >http://dx.doi.org/10.1111/bjh.14549</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.14549" target="_blank" >10.1111/bjh.14549</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Popis výsledku v původním jazyce
A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM). This post hoc analysis examined outcomes from ASPIRE in patients categorised by age. In the carfilzomib group, 103/396 patients were 70years old, and in the control group, 115/396 patients were 70years old. Median PFS for patients <70years old was 286months for the carfilzomib group versus 176months for the control group [hazard ratio (HR), 0701]. Median PFS for patients 70years old was 238months for the carfilzomib group versus 160months for the control group (HR, 0753). For patients <70years the overall response rate (ORR) was 860% (carfilzomib group) and 669% (control group); for patients 70years old the ORR was 903% (carfilzomib group) and 661% (control group). Within the carfilzomib group, grade 3 cardiovascular adverse events occurred more frequently among patients 70years old compared with patients <70years old. Carfilzomib-lenalidomide-dexamethasone has a favourable benefit-risk profile for patients with RMM, including elderly patients 70years old. Trial Registration: clinicaltrials.gov identifier: NCT01080391.
Název v anglickém jazyce
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Popis výsledku anglicky
A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM). This post hoc analysis examined outcomes from ASPIRE in patients categorised by age. In the carfilzomib group, 103/396 patients were 70years old, and in the control group, 115/396 patients were 70years old. Median PFS for patients <70years old was 286months for the carfilzomib group versus 176months for the control group [hazard ratio (HR), 0701]. Median PFS for patients 70years old was 238months for the carfilzomib group versus 160months for the control group (HR, 0753). For patients <70years the overall response rate (ORR) was 860% (carfilzomib group) and 669% (control group); for patients 70years old the ORR was 903% (carfilzomib group) and 661% (control group). Within the carfilzomib group, grade 3 cardiovascular adverse events occurred more frequently among patients 70years old compared with patients <70years old. Carfilzomib-lenalidomide-dexamethasone has a favourable benefit-risk profile for patients with RMM, including elderly patients 70years old. Trial Registration: clinicaltrials.gov identifier: NCT01080391.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
BRITISH JOURNAL OF HAEMATOLOGY
ISSN
0007-1048
e-ISSN
1365-2141
Svazek periodika
177
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
404-413
Kód UT WoS článku
000399957200010
EID výsledku v databázi Scopus
2-s2.0-85013483834